OCEA vs. MRKR, MEIP, QNTM, AFMD, SLGL, SPRB, SYBX, GOVX, NRSN, and EGRX
Should you be buying Ocean Biomedical stock or one of its competitors? The main competitors of Ocean Biomedical include Marker Therapeutics (MRKR), MEI Pharma (MEIP), Quantum Biopharma (QNTM), Affimed (AFMD), Sol-Gel Technologies (SLGL), Spruce Biosciences (SPRB), Synlogic (SYBX), GeoVax Labs (GOVX), NeuroSense Therapeutics (NRSN), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "pharmaceutical preparations" industry.
Ocean Biomedical vs.
Marker Therapeutics (NASDAQ:MRKR) and Ocean Biomedical (NASDAQ:OCEA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, community ranking and media sentiment.
Marker Therapeutics currently has a consensus target price of $19.00, indicating a potential upside of 1,110.19%. Given Marker Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Marker Therapeutics is more favorable than Ocean Biomedical.
Marker Therapeutics received 69 more outperform votes than Ocean Biomedical when rated by MarketBeat users. However, 100.00% of users gave Ocean Biomedical an outperform vote while only 64.04% of users gave Marker Therapeutics an outperform vote.
Ocean Biomedical has a net margin of 0.00% compared to Marker Therapeutics' net margin of -179.74%. Ocean Biomedical's return on equity of 0.00% beat Marker Therapeutics' return on equity.
Marker Therapeutics has higher revenue and earnings than Ocean Biomedical.
22.4% of Marker Therapeutics shares are owned by institutional investors. Comparatively, 24.6% of Ocean Biomedical shares are owned by institutional investors. 14.5% of Marker Therapeutics shares are owned by company insiders. Comparatively, 73.5% of Ocean Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Marker Therapeutics' average media sentiment score of 0.55 beat Ocean Biomedical's score of 0.00 indicating that Marker Therapeutics is being referred to more favorably in the media.
Marker Therapeutics has a beta of 1.44, meaning that its stock price is 44% more volatile than the S&P 500. Comparatively, Ocean Biomedical has a beta of 1.31, meaning that its stock price is 31% more volatile than the S&P 500.
Summary
Marker Therapeutics beats Ocean Biomedical on 10 of the 15 factors compared between the two stocks.
Get Ocean Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCEA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ocean Biomedical Competitors List
Related Companies and Tools
This page (NASDAQ:OCEA) was last updated on 2/23/2025 by MarketBeat.com Staff
